EIPM Seminar Series: "From Organoids to Algorithms: Translational Platforms for Precision Oncology in Solid Tumors" Dr. Marianna Kruithof-de Julio

Englander Institute for Precision Medicine Seminar Series “From Organoids to Algorithms: Translational Platforms for Precision Oncology in Solid Tumors” Presented by Marianna Kruithof-de Julio, Ph.D. Professor of Experimental Urology, Director, Cancer Translational Research Program, Director, Organoid CORE, University of Bern, CH. Biography: Marianna Kruithof-de Julio is a Professor of Experimental Urology and Director of the Cancer Translational Research Program at the University of Bern. She leads the Urology Research Laboratory and the Organoid Core Facility, developing patient-derived organoid and organ-on-chip models to better understand cancer and support therapy decisions. Her work focuses on prostate, bladder, renal, and pancreatic cancers, combining advanced technologies such as spatial transcriptomics and AI-driven histopathology with functional drug screening. In addition to her research, she serves as Editor-in-Chief of Gene and is Founder of OnconiX, committed to translating science into practical solutions that improve patient care. Abstract: The complexity of solid tumors such as pancreatic ductal adenocarcinoma (PDAC) and bladder cancer (BLCa) demands integrative approaches that combine biological fidelity with computational power. Here we outline a multi-modal translational framework that leverages patient-derived organoids, spatial transcriptomics, microfluidic platforms, and artificial intelligence to accelerate personalized cancer therapy development. Feasibility trials in PDAC have demonstrated the successful acquisition of high-quality biopsies for downstream applications, including organoid generation and spatial profiling. These models recapitulate key histopathological and molecular features, enabling functional drug screening and predictive modeling. AI-based classifiers trained on transcriptomic data further stratify tumors by therapeutic response, even in cases where organoid derivation is not feasible. Complementing this, the iBloC (immune Bladder-on-Chip) platform introduces a microfluidic system tailored for bladder cancer, simulating tumor-immune interactions under physiologically relevant conditions. This chip-based model supports dynamic drug testing and real-time molecular analysis, bridging the gap between preclinical research and clinical application. Together, these platforms represent a scalable and clinically relevant pipeline for precision oncology, integrating experimental and computational tools to guide individualized treatment strategies.